Partial
Mostly Aligned
Patient Risk:
Low
Summary
Some core label-supported points are accurate (brand composition equivalence, indications including vaginal/oropharyngeal/esophageal/cryptococcal/prophylaxis, and antifungal mechanism elements). However, several claims are unsupported or misaligned with the provided label text—most notably adverse reactions listing and multiple mechanism/ergosterol/cell-membrane details not stated verbatim. Also, multiple efficacy-spectrum and generic/patent/cost statements are not part of the provided prescribing information.
Category Scores
Accurate Statements
Diflucan is a brand name for fluconazole.
DESCRIPTION: “DIFLUCAN (fluconazole)”
Fluconazole is an antifungal medication used to treat a variety of fungal infections.
INDICATIONS AND USAGE: indications for multiple Candida infections and cryptococcal meningitis
Fluconazole belongs to the class of triazole antifungals.
DESCRIPTION: “first of a new subclass of synthetic triazole antifungal agents”
Fluconazole functions by inhibiting the synthesis of ergosterol.
Mechanism of Action: lanosterol 14-α-demethylase converts lanosterol to ergosterol; loss of normal sterols
Fluconazole inhibits ergosterol production, which weakens fungal cell membranes.
Mechanism of Action: loss of normal sterols correlates with accumulation of 14-α-methyl sterols; label does not explicitly mention cell membranes
Fluconazole targets fungal cells because human cell membranes contain cholesterol instead of ergosterol.
Mechanism of Action: “Mammalian cell demethylation is much less sensitive to fluconazole inhibition.” (label does not explicitly state cholesterol vs ergosterol)
Fluconazole is prescribed for candidiasis (yeast infections), including vaginal yeast infections.
INDICATIONS AND USAGE item 1: “Vaginal candidiasis (vaginal yeast infections due to Candida)”
Fluconazole is prescribed for oral thrush.
INDICATIONS AND USAGE item 2: “Oropharyngeal candidiasis”
Fluconazole is prescribed for Candida infections of the esophagus.
INDICATIONS AND USAGE item 2: “Oropharyngeal and esophageal candidiasis.”
Fluconazole is prescribed for cryptococcal meningitis.
INDICATIONS AND USAGE item 3: “Cryptococcal meningitis.”
Cryptococcal meningitis is described as a serious fungal infection of the brain and spinal cord.
No supporting text in the provided label excerpts for “brain and spinal cord” or “serious”
Fluconazole is prescribed for prevention of candidiasis in patients with weakened immune systems.
Prophylaxis: indication to decrease incidence of candidiasis in “patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.” (label excerpt does not mention weakened immune systems)
Fluconazole prevention of candidiasis is used in patients undergoing bone marrow transplantation.
Prophylaxis: “patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.”
Fluconazole is effective against a broad spectrum of fungi.
No explicit “broad spectrum of fungi” statement in the provided excerpts
Other antifungal medications may work through different mechanisms.
No supporting text in the provided excerpts
The choice of antifungal medication depends on the specific type of fungal infection, its severity, and the patient's individual health status.
No supporting text in the provided excerpts
Unsupported Statements
Fluconazole inhibits ergosterol production, which weakens fungal cell membranes.
The provided Mechanism of Action describes loss of normal sterols and accumulation of 14-α-methyl sterols and fungistatic activity, but does not mention “weakens fungal cell membranes.”
By disrupting ergosterol production, fluconazole increases membrane permeability and leads to eventual cell death.
The provided Mechanism of Action discusses loss of sterols and fungistatic activity; it does not state increased membrane permeability or eventual cell death.
Fluconazole targets fungal cells because human cell membranes contain cholesterol instead of ergosterol.
The provided Mechanism of Action mentions mammalian demethylation being less sensitive, but does not state that human membranes contain cholesterol instead of ergosterol.
Fluconazole is prescribed for Candida infections of the skin.
Provided Indications and Usage do not list skin Candida infections.
Fluconazole is prescribed for Candida infections of the urinary tract.
Urinary tract Candida infections are mentioned only as effective in open noncomparative studies (not as an explicit labeled indication).
Cryptococcal meningitis is described as a serious fungal infection of the brain and spinal cord.
No such description appears in the provided label excerpts.
Fluconazole prevention of candidiasis is used in patients undergoing chemotherapy.
The prophylaxis indication includes “cytotoxic chemotherapy and/or radiation therapy” but does not state chemotherapy alone; phrasing is incomplete/unsupported as “used in patients undergoing chemotherapy”.
Common adverse reactions of fluconazole include headache.
The provided Adverse Reactions section does not list headache as a common adverse reaction.
Common adverse reactions of fluconazole include nausea.
The provided Adverse Reactions section does not list nausea as a common adverse reaction.
Common adverse reactions of fluconazole include vomiting.
The provided Adverse Reactions section does not list vomiting as a common adverse reaction.
Common adverse reactions of fluconazole include diarrhea.
The provided Adverse Reactions section does not list diarrhea as a common adverse reaction.
Common adverse reactions of fluconazole include abdominal pain.
The provided Adverse Reactions section does not list abdominal pain as a common adverse reaction.
Common adverse reactions of fluconazole include changes in taste.
The provided Adverse Reactions section does not list changes in taste as a common adverse reaction.
More serious side effects of fluconazole can occur and may require medical attention.
The excerpt does not provide this statement; warnings discuss hepatic injury, anaphylaxis, dermatologic reactions, and fetal harm, but does not include “may require medical attention.”
Information regarding the patent exclusivity for Diflucan can be found on DrugPatentWatch.com.
Not present in the provided label excerpts.
Once the patent protection for Diflucan expires, generic versions of fluconazole can be manufactured and sold.
Not present in the provided label excerpts.
Generic drugs contain the same active ingredient as their brand-name counterparts.
Not present in the provided label excerpts.
Generic drugs are generally considered therapeutically equivalent to their brand-name counterparts.
Not present in the provided label excerpts.
The availability of generic fluconazole typically leads to lower medication costs.
Not present in the provided label excerpts.
Fluconazole is effective against a broad spectrum of fungi.
No explicit “broad spectrum” effectiveness statement appears in the provided excerpts.
Other antifungal medications may work through different mechanisms.
Not present in the provided label excerpts.
The choice of antifungal medication depends on the specific type of fungal infection, its severity, and the patient's individual health status.
Not present in the provided label excerpts.
Contradictions
Important Omissions
Dosage and administration details (dose, frequency, duration, dosing adjustments) were not provided/assessed.
Importance:
Moderate
Contraindications section was not included in the provided label text, limiting assessment of related claims.
Importance:
Moderate
Boxed warnings were not provided in the excerpt; therefore, any boxed-warning-related claims cannot be evaluated.
Importance:
Moderate
The AI did not align adverse reaction claims with the provided label text, which contains no list of common adverse reactions in the excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-mismatched safety content in the excerpt is the listing of specific “common adverse reactions” (headache, nausea, vomiting, diarrhea, abdominal pain, changes in taste), which is unsupported by the provided label text. The remaining claims are largely efficacy/education statements and do not directly provide dosing or contraindication instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported/incorrectly specific adverse reaction listings and several mechanism/clinical description claims not supported by the provided label excerpts; some indication claims (skin Candida) are not present as labeled indications in the supplied text.
Suggested Improvement
Limit mechanism statements to the provided label wording (lanosterol 14-α-demethylase inhibition, ergosterol/sterol changes) without adding membrane-permeability/cell-death language. Remove or rephrase adverse reaction “common” lists unless supported by the label excerpt. Restrict indications to those explicitly listed (vaginal/oropharyngeal/esophageal candidiasis, cryptococcal meningitis, and prophylaxis in bone marrow transplant with cytotoxic chemo and/or radiation) as shown in the supplied text.